# " Evaluation of Erythropoietin Therapy in Patients With End-Stage Kidney Disease on Regular Hemodialysis: Hemoglobin Outcomes, and Metabolic Syndrome as a Risk Factor for Erythropoietin Resistance "

> **NCT06983756** · — · NOT_YET_RECRUITING · sponsor: **Fayoum University** · enrollment: 66 (estimated)

## Conditions studied

- Erythropoietin Resistant Anemia (EPO Resistant Anemia)

## Interventions

- **DRUG:** Erythropoietin

## Key facts

- **NCT ID:** NCT06983756
- **Lead sponsor:** Fayoum University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06-01
- **Primary completion:** 2025-12-01
- **Final completion:** 2026-01-01
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2025-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06983756

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06983756, "" Evaluation of Erythropoietin Therapy in Patients With End-Stage Kidney Disease on Regular Hemodialysis: Hemoglobin Outcomes, and Metabolic Syndrome as a Risk Factor for Erythropoietin Resistance "". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06983756. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*